PP56. GLIOBLASTOMA OUTCOMES: THE UCLH / NHNN EXPERIENCE 2010–2016
| Autor: | DE Wilson, DJ Rees, DF Solda, DM Kosmin, DN Fersht |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Cancer Research
medicine.medical_specialty medicine.diagnostic_test business.industry medicine.medical_treatment Maximal Debulking ECOG Performance Status O-6-methylguanine-DNA methyltransferase medicine.disease Debulking Gastroenterology Radiation therapy Abstracts Text mining Oncology Internal medicine Biopsy medicine Neurology (clinical) business Glioblastoma |
| Zdroj: | Neuro-Oncology. 19:i15-i16 |
| ISSN: | 1523-5866 1522-8517 |
| DOI: | 10.1093/neuonc/now293.056 |
| Popis: | INTRODUCTION: Chemo-radiotherapy (CRT) after maximal debulking surgery is the standard of care for patients with glioblastoma (GBM). This study reviews patient outcomes at our centre. Published data show worse outcomes for patients who present with GBM through A&E. This study further investigates this phenomenon by analysing outcomes for those patients fit enough to be treated with radical CRT. METHODS: Patients with GBM operated on between 1 April 2010 and 5 October 2015 at NHNN, and then treated with CRT at UCLH, were included in the study cohort. Data on patient and tumour characteristics, initial patient presentation, CRT treatment and patient outcomes (progression (PFS) and overall survival (OS)) were collected from the electronic patient records and radiotherapy planning systems. Outcome data were censored on 22 March 2016. Survival analysis was performed using logrank test. RESULTS: 134 patients were included in the analysis (55% male, 45% female). They had a median OS of 16 months, and median PFS of 10 months from start of CRT. 70% patients were alive at 1 year; 41% at 2 years. Improved OS was associated with ECOG performance status (PS=0 vs PS>0; p = 0.00212), type of surgery (biopsy vs partial/complete debulk; p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|